Fiducial Marker Sales Aided by Growing Preference for Image Guided Radiotherapy: Fact.MR

Rockville, United States, 2021-Feb-10 — /EPR Network/ —

Award winning market research company Fact.MR has recently published an extensive coverage on the global fiducial markers market. According to the study, the market is poised to make significant progress in 2021, registering a positive annual growth. Growth for the next decade also appears positive, with Fact.MR projecting a CAGR exceeding 4% from 2021-2031.

fiducial markers market region

The market is expected to ride on the coattails of increasing emphasis on advanced cancer research and treatment. The International Agency for Research on Cancer (IARC) estimates that globally, 1 in 5 people develop cancer during their lifetime, with over 12% of men and 9% of women succumbing to the disease. Furthermore, over 50 million people currently live within five years of a past diagnosis. Hence, efforts to bolster oncology research have registered an uptick, providing fertile ground for fiducial markers expansion.

Over the years, fiducial markers have emerged as the gold standard for image guided radiotherapy, prompting manufacturers to introduce new products into the global market. As governments in emerging countries bolster efforts to improve healthcare access, the scope for fiducial markers is poised to enhance in forthcoming years. Studies suggest that the number of patients expected to benefit from radiotherapy range from 40-62%. Demand is slated to remain especially high amongst older patients with solid tumors.

The Global Taskforce on Radiotherapy for Cancer Control (GTFRCC) discovered that by 2035, nearly 12 million cancer patients would benefit from radiotherapy, with the potential to save 950,000 lives and help control cancer for 2.5 million people globally.

“Cutting-edge technology penetration has led to prolific advancements in fiducial markers, with manufacturers effectively leveraging advancements such as precision based imaging to assist healthcare providers in achieving higher accuracy in oncology treatment procedures,” says the Fact.MR analyst.

Request a Sample Report here

Key Takeaways from Fact.MR’s Fiducial Markers Study

  • Pure gold fiducial markers are expected to remain lucrative, attributed to extensive adoption in treating prostate cancer
  • Photon therapy to emerge as the primary modality, owing to greater effectiveness in inhibiting cancer cells multiplication
  • By disease site, prostate cancer treatment to remain principal application area, lung cancer treatment to proliferate
  • Radiotherapy centers to account for majority of fiducial markers deployment, attributed to numerous coalitions with agencies to foster cancer research
  • U.S. to account for a lucrative market fiducial marker share, with an increase in the number of oncology treatment centers
  • Growing incidences of breast cancer to fuel fiducial marker sales across Germany
  • U.K. to witness steady annual expansion amid rapid advancements in image guide therapeutic procedures
  • High geriatric population pool and the resultant increase in cancer treatment to augment sales across IndiaChinaJapan and South Korea respectively

Competitive Landscape

Key fiducial markers manufacturers profiled in Fact.MR’s report include Eckert & Zieglar BEBIG, Innovative Oncology Solutions, Boston Scientific, IBA, Best Medical International Inc., IZI Medical Products, Carbon Medical Technologies, CIVCO, AlphaXRT, Nanovi A/S and Stellar Medical. Players are attempting to establish a firm footing by diversifying existing portfolios through new product launches and other inorganic strategies.

In 2018, Boston Scientific introduced the LumiCoil Platinum Fiducial Markers featuring platinum construction designed for clear visibility in CT, X-Ray, EUS, CBCT and MRI procedures. This device has immensely helped achieve precision in radiation delivery, leaving healthy tissues undamaged.

In March 2020, Nanovi A/S earned the CE mark for its BioXmark® novel liquid fiducial marker intended for marking soft body tissues for enhanced visibility on medical imaging, thus facilitating high precision radiation therapy. It consists of an adhesive-like iodine-based soft marker for adaptability to surrounding tissues, positional stability and visibility on relevant imaging modalities.

Request Customized Report here

More Valuable Insights on Fiducial Markers Market

In the latest report by Fact.MR, we offer an unbiased analysis of the global fiducial markers market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of product (metal-based, polymer-based, and others) and cancer type (lung cancer, breast cancer, prostate cancer, and others), across seven major regions of the world (North AmericaLatin AmericaEuropeEast AsiaSouth Asia, Oceania, and MEA).

Key Questions Covered in the Report:

  • Which segment accounted for the largest fiducial markers market share?
  • What are the factors driving the fiducial markers market?
  • Are Investments by Governments Fuelling Sales of Fiducial Markers?
  • What are the Key Challenges Faced by Fiducial Marker Manufactures?
  • Why are Fiducial Marker Manufacturers Eyeing the United States?

Get Our Popular Research Reports Here>>>>

About Fact.MR

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. We are headquartered in Dubai, and operate from our sales office in Dublin, Ireland. Reach out to us with your goals, and we’ll be an able research partner.


US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU), 
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates

Matched content

Editor’s pick

Express Press Release Distribution